Edition:
United States

Neurotrope Inc (NTRP.OQ)

NTRP.OQ on NASDAQ Stock Exchange Capital Market

9.35USD
23 Feb 2018
Change (% chg)

$0.70 (+8.09%)
Prev Close
$8.65
Open
$8.65
Day's High
$9.40
Day's Low
$8.56
Volume
14,605
Avg. Vol
8,868
52-wk High
$21.31
52-wk Low
$3.41

Latest Key Developments (Source: Significant Developments)

Neurotrope Appoints Charles S. Ryan As CEO
Monday, 18 Dec 2017 08:30am EST 

Dec 18 (Reuters) - Neurotrope Inc ::NEUROTROPE APPOINTS CHARLES S. RYAN AS CHIEF EXECUTIVE OFFICER.NEUROTROPE INC - ‍ APPOINTMENT OF CHARLES RYAN FOLLOWS RESIGNATION OF SUSANNE WILKE, PHD, AS CHIEF EXECUTIVE OFFICER AND DIRECTOR​.NEUROTROPE INC - RYAN BECOMES A DIRECTOR OF COMPANY EFFECTIVE IMMEDIATELY AND WILL ASSUME HIS RESPONSIBILITIES AS CEO EFFECTIVE FEBRUARY 15, 2018.  Full Article

Neurotrope to provide detailed Alzheimer's drug data in coming months
Monday, 1 May 2017 07:54am EDT 

May 1 (Reuters) - Neurotrope Inc -:Neurotrope CEO says 1 patient on the 20 mcg arm and 3 on the 40 mcg arm dropped out of the study: conf call.Neurotrope CSO: in this very seriously afflicted population, the rate of dropouts in the trial was typical: conf call.Neurotrope CSO: stat significance in a phase 3 trial is usually defined by p value of 0.05, but this was a more exploratory phase 2 trial, and the data is encouraging.Neurotrope CSO expects to provide more detailed results in coming months.Neurotrope CEO says co is interested in finding a corporate partner to move forward with.Neurotrope CSO: "we saw very modest efficacy from the 40 mcg".  Full Article

Neurotrope announces positive top-line results from Phase 2 study of Bryostatin-1
Monday, 1 May 2017 06:30am EDT 

May 1 (Reuters) - Neurotrope Inc : :Neurotrope announces positive top-line results from Phase 2 study of Bryostatin-1 for moderate to severe Alzheimer’S disease.Results indicate 20 μg dose,administered every 2 weeks,met pre-specified primary endpoint in Completer population, not in mITT population.Data indicate that Bryostatin-1 improves cognition and ability to perform activities of daily living.Plans to meet with FDA to address clinical and regulatory path forward for Bryostatin-1.  Full Article

Neurotrope files for mixed shelf of up to $100 million
Friday, 31 Mar 2017 05:40pm EDT 

Neurotrope Inc :Files for mixed shelf of up to $100 million - sec filing.  Full Article

BRIEF-Neurotrope's Bryostatin Improves Cognition In Patients

* NEUROTROPE'S BRYOSTATIN IMPROVES COGNITION IN PATIENTS WITH ADVANCED ALZHEIMER'S DISEASE BASED ON FURTHER ANALYSIS OF PHASE 2 CLINICAL TRIAL DATA Source text for Eikon: Further company coverage: